MOTS-c injection sites: where it's given in the studies

Last updated 2026-07-25

Where has MOTS-c actually been injected in research?

In the foundational 2015 Cell Metabolism paper, MOTS-c was delivered to mice by injection, and the peptide's effect on glucose homeostasis and insulin resistance was measured after that dosing ^[1]. The 2018 Cell Metabolism paper describing MOTS-c's translocation to the nucleus under metabolic stress also used injected peptide in mouse and cell models ^[2]. That's the honest starting point. Almost every MOTS-c study on PubMed right now is rodent work, cell culture work, or a review of rodent and cell work. A 2023 Frontiers in Endocrinology review calls MOTS-c "a promising mitochondrial-derived peptide for therapeutic exploitation" ^[3], which is a fair summary, but "promising for exploitation" is not the same as "validated in humans with a known injection protocol." Nobody has published a controlled human trial establishing an optimal injection site, needle gauge, or depth for MOTS-c. If you see a specific site (say, periumbilical subcutaneous fat versus deltoid subcutaneous fat) recommended with confidence, that recommendation is coming from general peptide-injection convention, not from MOTS-c-specific human data. This matters for how you read the rest of this piece. We can tell you what routes researchers use in animal studies, and we can tell you what the peptide-compounding regulatory landscape looks like. We can't tell you a human-validated site because that study hasn't been done. For a related storage-and-handling question, see does MOTS-c need to be refrigerated.

Subcutaneous vs intraperitoneal: what's the difference and why does it show up in MOTS-c papers?

Subcutaneous (SC) injection puts the peptide into the fat layer just under the skin, where it diffuses into local capillaries over minutes to hours. Intraperitoneal (IP) injection, used almost exclusively in rodent research, puts the compound directly into the abdominal cavity, where it's absorbed quickly across the peritoneal membrane. IP dosing is standard in mouse metabolic studies because it's fast, reliable, and doesn't require the fine technique that IV or SC dosing in a 25-gram mouse demands. The original MOTS-c metabolic homeostasis paper used injected peptide in diet-induced-obesity and aged mouse models to show reduced obesity and insulin resistance ^[1]. Studies on MOTS-c in gestational diabetes mellitus models used a similar injected-peptide approach to show relief of hyperglycemia and insulin resistance ^[4]. None of this establishes an SC-vs-IP equivalence in humans, because human trials haven't been run. Extrapolating a mouse IP dose or an SC dose in a mouse to a human injection site is a guess, not a translation backed by pharmacokinetic data. If you're comparing this to something like does MOTS-c need to be refrigerated, the storage question at least has a straightforward peptide-stability answer. The injection site question doesn't, because the human dosing studies that would answer it don't exist yet. If you're weighing a source at all, the sourcing question, covered in how to verify MOTS-c quality, matters more than technique.

Does the "exercise in a pill" framing tell us anything about injection site or dose?

No. "Exercise mimetic" is a description of a biological hypothesis, not a dosing protocol. A 2022 Diabetes & Metabolism Journal paper on exercise, mitohormesis, and MOTS-c describes circulating MOTS-c levels rising with exercise and proposes it as a signaling molecule linking muscle activity to systemic metabolism ^[5]. A 2021 review in Biochimica et Biophysica Acta General Subjects covers mitochondrial-derived peptides and exercise more broadly, again describing associations between exercise and MDP levels rather than a therapeutic injection protocol ^[6]. That's interesting biology. It is not the same claim as "inject MOTS-c here and get exercise's metabolic benefits." The marketing shorthand skips past the fact that these are observational associations in exercise physiology, layered on top of separate rodent injection studies showing metabolic effects. Nobody has run a trial injecting MOTS-c into sedentary humans at a specified site and dose, then compared outcomes to an exercise group. Until that trial exists, "exercise in a pill" is a hypothesis being marketed as a conclusion. A 2023 Metabolites paper titled "MOTS-c Functionally Prevents Metabolic Disorders" reinforces the mechanistic story in preclinical models ^[7], and a 2023 Diabetes & Metabolism Journal review ties MOTS-c to diabetes and aging-related disease pathways ^[8]. Both are legitimate contributions to understanding mechanism. Neither is a human injection-site guide.

What doses have researchers actually used in animal studies?

Published rodent studies commonly use MOTS-c doses in the range of roughly 0.5 to 15 mg/kg body weight, delivered by IP or SC injection, depending on the specific model and outcome being studied. That range spans acute metabolic-challenge experiments through chronic dosing studies in aged or obese mice. There is no consensus human-equivalent dose published in a peer-reviewed human trial, because no such trial has been published. Converting a mouse mg/kg dose to a human dose using standard allometric scaling (the FDA's body-surface-area conversion approach, for example) is a common practice in early drug development, but it produces a starting estimate for a future trial, not a validated therapeutic dose. Any specific human dose you see quoted online is either derived from that kind of back-of-envelope scaling, or it's simply copied from another vendor's marketing material without a cited source. We'd flag this hard: dose and injection site are not separable questions. A wrong dose delivered via a textbook-perfect injection site is still a wrong dose. Anyone giving you a confident human number without citing a human trial is guessing.

Is MOTS-c legal to buy and inject in the US right now?

This is a regulatory question, not a biology one, and it matters more than most buyers realize. MOTS-c is not an FDA-approved drug. It does not appear in Drugs@FDA, the FDA's database of approved drug products ^[9]. It is also not on the FDA's current list of bulk drug substances nominated for use in compounding under section 503A ^[10], and it's not on the 503A or 503B Bulks Lists codified at 21 CFR 216.23 and 216.24 ^[11][12]. Practically, that means a state-licensed 503A compounding pharmacy can't legally compound MOTS-c into a patient-specific prescription using the bulk drug substance provisions under 21 U.S.C. 353a ^[13], because MOTS-c hasn't cleared FDA's bulk substance review for compounding. Products sold outside a legitimate prescription and compounding relationship, most commonly labeled "research use only," fall outside that framework entirely, and FDA's own guidance on intended use, 21 CFR 201.128, ties a product's legal status to how it's actually marketed and used, more than what the label says ^[14]. A vial labeled "not for human use" that's clearly being sold and used for self-injection sits in a legal gray zone at best. If you're evaluating whether a source is legitimate, read how to verify MOTS-c quality before you read anything about injection technique. Site and depth are moot points if the vial's contents, purity, or legal status are in question.

What does the safety and injury-therapy literature say about peptide injection practices generally?

A 2026 Sports Medicine paper reviews the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[15]. That review sits squarely in the category MOTS-c would fall into if it were being used off-label for performance or recovery purposes: a peptide with legitimate mechanistic interest and thin-to-absent human trial data, being used anyway in athletic and biohacking circles ahead of the evidence. That pattern (mechanistic promise outrunning clinical validation) shows up across the mitochondrial-derived peptide family, more than MOTS-c. A 2018 Rejuvenation Research paper actually found that mitochondrial-derived peptides can, in some contexts, exacerbate senescence ^[16], a reminder that this biology isn't uniformly protective and that context (cell type, dose, disease state) changes the direction of the effect. That's the opposite of a marketing-friendly finding, and it's exactly why blanket claims about MOTS-c's safety profile in humans should make you skeptical, not reassured.

What has MOTS-c been shown to do in cell and animal models, beyond metabolism?

The mechanistic breadth here is genuinely striking, and it's worth listing plainly, with the label attached each time: rodent or cell model, not human trial. MOTS-c binds and activates CK2 to modulate skeletal muscle function in a 2024 iScience paper ^[17], and separately promotes muscle differentiation in vitro per a 2022 Peptides study ^[18]. In immobilization-induced muscle atrophy, MOTS-c reduced lipid infiltration in a 2024 American Journal of Physiology Endocrinology and Metabolism study ^[19], and a 2021 paper in the same journal found MOTS-c reduces myostatin and muscle atrophy signaling ^[20]. In bone metabolism, a 2023 Frontiers in Physiology review describes MOTS-c's regulatory role ^[21], and a 2025 Free Radical Biology & Medicine paper found MOTS-c attenuates cartilage degradation in osteoarthritis models via an Nrf2-dependent mechanism ^[22]. Outside the muscle-bone-metabolic axis, MOTS-c shows an antiviral function during HBV infection through mitochondrial remodeling (Gut, 2024) ^[23], helps repair plasma membranes by facilitating TRIM72 translocation (Theranostics, 2024) ^[24], suppresses ferroptosis in a lung injury model tied to myocardial ischemia reperfusion (European Journal of Pharmacology, 2023) ^[25], and shows anti-fibrotic activity in a 2023 Mitochondrion paper on pulmonary fibrosis ^[26]. A 2024 Advanced Science paper even found MOTS-c suppresses ovarian cancer progression by a specific ubiquitination mechanism ^[27]. This is a peptide with its fingers in an unusual number of pathways. None of that breadth tells you where to inject it in a human, because none of these are human injection studies.

How do MOTS-c's mechanisms differ from a standard hormone or exercise mimetic?

MOTS-c is unusual because it's encoded within the mitochondrial genome (in a small open reading frame inside the 12S rRNA region) but acts, at least in part, inside the cell nucleus. A 2018 Cell Metabolism paper found that under metabolic stress, MOTS-c translocates to the nucleus and regulates nuclear gene expression, including antioxidant response genes ^[2]. A 2019 BioEssays review frames MOTS-c specifically as a mitochondrial-encoded regulator of nuclear activity ^[28], which is a genuinely unusual mode of action for a peptide this small. That nuclear-translocation mechanism shows up again in a 2025 Redox Biology paper, where MOTS-c attenuates lung ischemia-reperfusion injury through MYH9-dependent nuclear translocation and activation of antioxidant genes ^[29]. It's a coherent, mechanistically interesting story across multiple organ systems. But mechanistic coherence in mouse lungs and cultured cells is a different claim from clinical efficacy or an established human dosing route, and conflating the two is exactly the gap this whole article exists to flag.

What about MOTS-c in aging-related and cardiometabolic disease specifically?

This is where the mitochondrial-derived peptide (MDP) field gets its longevity buzz, and where the evidence gap is most consequential for readers evaluating hype. A 2023 Diabetes & Metabolism Journal review connects MOTS-c to diabetes and aging-related diseases mechanistically ^[8], and a 2025 Cardiovascular Drugs and Therapy paper asks directly whether MOTS-c is a "magical molecule" for diabetic cardiomyopathy ^[30], a framing that itself signals the paper is reviewing preclinical promise rather than reporting a clinical trial result. More specifically, a 2025 Experimental & Molecular Medicine paper found that MOTS-c prevents pancreatic islet cell senescence to delay diabetes in a preclinical model ^[31], and a 2025 Scientific Reports paper found MOTS-c mimics exercise-associated signaling to combat diabetic liver fibrosis by targeting the Keap1-Nrf2-Smad2/3 pathway ^[32]. Again: real, specific, mechanistically detailed findings. Again: rodent and cell models, not humans. If you're researching MOTS-c for its longevity angle, the honest summary is that the mechanistic case is dense and growing fast, while the human clinical case is currently empty.

Does sex or reproductive status change anything about MOTS-c's site or dosing considerations?

There's a specific human-relevant thread here worth flagging separately: MOTS-c has been studied in gestational diabetes mellitus contexts, with a 2022 Pharmacological Research paper finding that MOTS-c relieves hyperglycemia and insulin resistance in that model ^[4]. That's a pregnancy-adjacent metabolic condition, and it's a reminder that sex and reproductive status are not neutral variables in this research. If you want the fuller picture on how MOTS-c research treats female physiology specifically, including gaps in trial representation, read MOTS-c in women. We won't duplicate that analysis here, but the short version is that the gestational diabetes finding is preclinical, promising, and nowhere near sufficient to inform a real-world dosing or injection decision for a pregnant person, or anyone else.

So what should someone actually do with this information?

Read the mechanistic literature for what it is: a fast-growing, genuinely interesting body of rodent and cell-culture work spanning metabolism, muscle, bone, lung, liver, and even cancer biology [1-32]. Don't read a rodent IP or SC injection protocol as a human instruction. Don't take a vendor's confident injection-site diagram as evidence of anything beyond that vendor's marketing department. If you're going to use MOTS-c despite the human evidence gap (and that's a real choice some readers will make), the sourcing question matters more than the site question. A product's legal and quality status, whether it's actually MOTS-c at stated purity, whether it's coming through a chain with any pharmacy oversight, matters more to your actual safety than whether you inject at 45 or 90 degrees. Check how to verify MOTS-c quality first, and if storage or handling questions come up before you get that far, does MOTS-c need to be refrigerated covers that ground. Where a provider-reviewed pathway exists, with a licensed prescriber and a named pharmacy partner actually handling fulfillment, that's a meaningfully different risk profile than an unmarked vial from an unverifiable seller. MOTS-c Co's provider-reviewed route connects readers to that kind of pathway rather than compounding or selling anything directly. That doesn't resolve the human-data gap. It just means the product in the vial and the oversight around it are less likely to be the thing that hurts you.

Frequently asked questions

What injection site is best for MOTS-c?

No published human trial has established a best injection site for MOTS-c. Rodent studies use subcutaneous or intraperitoneal injection, but neither translates directly to a human recommendation. Any specific human site (abdomen, thigh, deltoid) you see recommended is based on general peptide-injection convention, not MOTS-c-specific human data ^[1][2].

Is MOTS-c injected subcutaneously or intramuscularly?

In published research, MOTS-c is given to rodents subcutaneously or intraperitoneally, not intramuscularly ^[1][4]. There is no peer-reviewed human study comparing subcutaneous, intramuscular, or intraperitoneal MOTS-c administration, so no route has been validated in humans specifically.

How much MOTS-c do researchers use in studies?

Rodent studies commonly use doses in roughly the 0.5 to 15 mg/kg range depending on the model, delivered by injection. No human dose has been established in a published clinical trial, and scaling a mouse dose to a human using standard conversion methods produces only a rough estimate, not a validated therapeutic dose.

Is MOTS-c FDA approved?

No. MOTS-c does not appear in Drugs@FDA, the FDA's database of approved drug products ^[9]. It's also absent from the FDA's current bulk drug substances nomination list for compounding ^[10] and from the 503A and 503B Bulks Lists at 21 CFR 216.23 and 216.24 ^[11][12].

Can a compounding pharmacy legally make MOTS-c?

A 503A pharmacy compounds under 21 U.S.C. 353a using bulk substances that have cleared FDA review for that purpose ^[13]. MOTS-c isn't on the 503A or 503B Bulks Lists ^[11][12] or FDA's nomination list ^[10], so a compliant compounding pathway for it currently doesn't exist in the way it does for approved bulk substances.

Does MOTS-c work like exercise in a pill?

That's marketing shorthand, not a proven claim. Circulating MOTS-c rises with exercise in observational research ^[5][6], and injected MOTS-c improves metabolic markers in mouse models ^[1]. No trial has injected MOTS-c into sedentary humans and compared outcomes to an exercise group, so the 'exercise in a pill' framing outruns the actual evidence.

Has MOTS-c been tested in human clinical trials?

Not in any peer-reviewed clinical trial we found. Every metabolic, muscle, bone, lung, liver, and cancer-related finding cited in this article comes from mouse models or cell culture [1-32]. That's the central evidence gap anyone evaluating MOTS-c against the hype needs to understand before anything else.

What does MOTS-c do for muscle in animal studies?

In rodent and cell models, MOTS-c binds and activates CK2 to affect muscle function ^[17], promotes muscle differentiation in vitro ^[18], reduces myostatin and atrophy signaling ^[20], and reduces lipid infiltration in immobilization-induced muscle atrophy ^[19]. These are preclinical findings, not confirmed human effects.

Is MOTS-c safe?

Safety hasn't been established in human trials specifically for MOTS-c. Broader peptide-therapy safety reviews, like a 2026 Sports Medicine paper on musculoskeletal and performance peptides, cover this category generally ^[15]. One 2018 paper even found mitochondrial-derived peptides can worsen senescence in certain contexts ^[16], showing effects aren't uniformly protective.

Does MOTS-c need refrigeration, and does that affect injection prep?

Storage and reconstitution stability are separate questions from injection site, but they affect how you prepare a dose. See does MOTS-c need to be refrigerated for the specifics on handling before injection.

Is MOTS-c different for women or during pregnancy-related conditions?

A 2022 Pharmacological Research paper found MOTS-c relieved hyperglycemia and insulin resistance in a gestational diabetes mellitus model ^[4], a preclinical finding, not a human safety clearance for pregnancy. See MOTS-c in women for a fuller look at sex-specific research gaps.

How do I know if a MOTS-c product is legitimate before injecting it?

Check whether the source works through a licensed prescriber and a named pharmacy partner rather than an unverifiable direct seller. See how to verify MOTS-c quality for specific checks on purity, sourcing, and legal status before you consider injection technique at all.

Sources

1. Cell Metabolism, 2015 (PMID 25738459): MOTS-c injected in mouse models promotes metabolic homeostasis and reduces obesity and insulin resistance
2. Cell Metabolism, 2018 (PMID 29983246): MOTS-c translocates to the nucleus and regulates nuclear gene expression in response to metabolic stress
3. Frontiers in Endocrinology, 2023 (PMID 36761202): Review describing MOTS-c as a promising mitochondrial-derived peptide for therapeutic exploitation
4. Pharmacological Research, 2022 (PMID 34798268): MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes mellitus model
5. Diabetes & Metabolism Journal, 2022 (PMID 35656563): Review of exercise, mitohormesis, and MOTS-c linking circulating peptide levels to exercise
6. Biochimica et Biophysica Acta General Subjects, 2021 (PMID 34520826): Review of mitochondrial-derived peptides and exercise associations
7. Metabolites, 2023 (PMID 36677050): MOTS-c functionally prevents metabolic disorders in preclinical models
8. Diabetes & Metabolism Journal, 2023 (PMID 36824008): Review connecting MOTS-c mechanistically to diabetes and aging-related diseases
9. FDA, Drugs@FDA database: MOTS-c does not appear as an FDA-approved drug product
10. FDA, bulk drug substances nominated for compounding (current list): MOTS-c is not on FDA's current list of bulk drug substances nominated for compounding use
11. 21 CFR 216.23, 503A Bulks List: MOTS-c is not included on the final 503A Bulks List for compounding
12. 21 CFR 216.24, 503B Bulks List: MOTS-c is not included on the 503B Bulks List for outsourcing facility compounding
13. 21 U.S.C. 353a, pharmacy compounding: Defines the legal framework under which 503A pharmacies may compound using approved bulk substances
14. 21 CFR 201.128, meaning of intended uses: A product's regulatory status depends on its intended use as marketed, not only its label claims
15. Sports Medicine, 2026 (PMID 41966639): Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance
16. Rejuvenation Research, 2018 (PMID 30058454): Mitochondrial-derived peptides can exacerbate senescence in certain contexts
17. iScience, 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2
18. Peptides, 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in vitro
19. American Journal of Physiology Endocrinology and Metabolism, 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration
20. American Journal of Physiology Endocrinology and Metabolism, 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling
21. Frontiers in Physiology, 2023 (PMID 37200834): Review of MOTS-c's role in bone metabolism regulation
22. Free Radical Biology & Medicine, 2025 (PMID 41043625): MOTS-c attenuates cartilage degradation in osteoarthritis via an Nrf2-dependent mechanism
23. Gut, 2024 (PMID 37788894): MOTS-c shows antiviral function during HBV infection via mitochondrial remodeling
24. Theranostics, 2024 (PMID 39267782): MOTS-c participates in plasma membrane repair by facilitating TRIM72 translocation
25. European Journal of Pharmacology, 2023 (PMID 37290680): MOTS-c suppresses ferroptosis and alleviates acute lung injury via PPARgamma signaling
26. Mitochondrion, 2023 (PMID 37307934): MOTS-c shows anti-pulmonary fibrosis activity in preclinical models
27. Advanced Science, 2024 (PMID 39321430): MOTS-c suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination
28. BioEssays, 2019 (PMID 31378979): Review framing MOTS-c as a mitochondrial-encoded regulator of nuclear activity
29. Redox Biology, 2025 (PMID 40403491): MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation of antioxidant genes
30. Cardiovascular Drugs and Therapy, 2025 (PMID 40172798): Review examining MOTS-c's potential role in diabetic cardiomyopathy
31. Experimental & Molecular Medicine, 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes in a preclinical model
32. Scientific Reports, 2025 (PMID 40425777): MOTS-c mimics exercise signaling to combat diabetic liver fibrosis via Keap1-Nrf2-Smad2/3